Talks
Gout in the ED
November 9, 2022
MicroRNAs in Gout
October 26, 2022
Influenza Vaccine
October 19, 2022
Tophaceous Gout
October 19, 2022
Probiotic Supplement
October 19, 2022
Depression with Gout
October 14, 2022
Management of Gout
October 12, 2022
Gout Response Rates
October 7, 2022
Low Urate in Gout
September 7, 2022
Gout and COVID19
September 6, 2022
Factors in Gout
September 6, 2022
Cardiovascular Event
September 6, 2022
Tophi in Gout?
August 18, 2022
Dual-Energy CT
August 18, 2022
Excess Uric Acid
August 18, 2022
Ruxolitinib Cream
May 20, 2022
Melasma
May 20, 2022
EHA 2022 Congress
May 19, 2022
Daratumumab
May 19, 2022
COVID19 in Derm
May 17, 2022
Treatment Expansion
April 22, 2022
Mortality Predictors
April 22, 2022
Induction Therapy
April 18, 2022
Dr. Krackhard
April 18, 2022
Dr. Tricot
April 6, 2022
Patient Needs
April 6, 2022
Early Stage TNBC
March 29, 2022
Dr. Kalinsky
March 29, 2022
Risk Stratification
March 25, 2022
Dr. Richardson
March 25, 2022
Future Prospects
March 21, 2022
Dr. Costa
March 21, 2022
MM
March 18, 2022
ASTCT
March 18, 2022
Autophagy
March 14, 2022
AJMC
March 14, 2022
Cevostamab
March 11, 2022
FDA Fast Track
March 11, 2022
Severe AD
March 11, 2022
Acne Vulgaris
March 11, 2022
therapeutics
March 11, 2022
Improving MM
March 9, 2022
Bispecific Antibody
March 9, 2022
GC Survival
March 8, 2022
Levatinib in HCC
March 8, 2022
Taxanes /Ramucirumab
March 8, 2022
Frontline Poziotinib
March 8, 2022
New FDA Approval
March 8, 2022
PET/CT Utility
March 7, 2022
Biospecific Antibody
March 7, 2022
Anti-CD38 Antibody
March 7, 2022
Neoadjuvant IO
March 7, 2022
HER2+BC
March 7, 2022
Dr. Tolaney
March 7, 2022
Non-Coding RNAs
March 4, 2022
Dr. Hurvitz
March 4, 2022
Dr. O’Shaughnessy
March 4, 2022
Proactive Care
March 2, 2022
Biomarkers
March 2, 2022
HER2-Low BC
February 28, 2022
Close button
Why are you reporting this TALK?